MEDI4736 (anti PD-L1) Combined with Gefitinib in Subjects with Non-Small Cell Lung Cancer(NSCLC).

Study identifier:D791PC00001

ClinicalTrials.gov identifier:NCT02088112

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 1

Healthy volunteers

No

Study drug

Gefitinib, MEDI4736

Sex

All

Actual Enrollment

56

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 24 Mar 2014
Primary Completion Date: 09 Mar 2021
Study Completion Date: 09 Mar 2021

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2022 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

AstraZeneca

Inclusion and exclusion criteria